Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study

Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5(7):649-657.

Publication Type:

Journal Article

Authors:

Feld, JJ; Cypel, M; Kumar, D; et, al

Source:

Lancet Gastroenterol Hepatol, Volume 5, Issue 7, p.649-657 (2020)

Cited On:

Treatment of HCV-Uninfected Transplant Recipients Receiving Organs From HCV-Viremic Donors

Export Citation:

RIS Format

Top